US EditionNew Compound Infuzide Shows Promise Against Resistant Bacterial Infections
- Researchers announced in 2025 that the new compound infuzide shows effectiveness against antibiotic-resistant Staphylococcus aureus infections in lab and mouse models.
- This research builds on over a decade of interdisciplinary work aimed at overcoming golden staph's rapid adaptation and multi-drug resistance, a major cause of severe infections globally.
- Infuzide kills bacteria through mechanisms distinct from existing antibiotics like vancomycin, reducing bacterial colonies faster and improving outcomes in resistant infections on mice skin.
- Co-Leader Michel Baltas emphasized that the straightforward nature of the chemical reactions enables production of these compounds on a large scale, supporting their potential for therapeutic application and further refinement.
- These findings suggest infuzide could contribute to targeted therapies against resistant infections and encourage clinical trials to help integrate precision antimicrobials into hospital treatments worldwide.
16 Articles
16 Articles
Doctors use real-time genomics to detect golden staph resistance and tailor life-saving therapies
Australian researchers have taken a major step toward using real-time genome sequencing in routine hospital care for patients with severe Staphylococcus aureus infections, or "golden staph," a superbug responsible for more than 1 million deaths globally each year.
News Medical
MSNNew compound infuzide shows promise against resistant bacterial infections
Antimicrobial resistance directly causes more than 1 million deaths every year and contributes to more than 35 million more, according to the World Health Organization. Staphylococcus aureus and Enterococcus sp., 2 gram-positive pathogens highly likely to develop resistance to known treatments, can cause dangerous hospital-acquired and community-acquired infections.
Why Are 90% of India’s Drug-Resistant Infections Going Untreated?
In 2019, India faced over a million carbapenem-resistant Gram-negative (CRGN) infections, but only 7.8% were treated with appropriate antibiotics. A new Lancet study exposes a deadly treatment gap that worsens the antimicrobial resistance (AMR) crisis.
Molecular typing of clinical, colonizing, and environmental isolates of Staphylococcus aureus and comparison with World isolates
Staphylococcus aureus (S.aureus) is a facultative anaerobe that colonizes humans' nasal cavity, skin, and other mucosal surfaces. The bacterium can cause local and systemic infections, including skin and soft tissue infections, bacteremia, endocarditis, and osteomyelitis. It...
Coverage Details
Bias Distribution
- 80% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
